9 Meters Biopharma, Inc. (NMTR): Price and Financial Metrics


9 Meters Biopharma, Inc. (NMTR): $0.45

-0.03 (-6.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NMTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NMTR Stock Price Chart Interactive Chart >

Price chart for NMTR

NMTR Price/Volume Stats

Current price $0.45 52-week high $1.55
Prev. close $0.48 52-week low $0.35
Day low $0.45 Volume 1,146,900
Day high $0.49 Avg. volume 1,353,752
50-day MA $0.49 Dividend yield N/A
200-day MA $0.88 Market Cap 116.05M

9 Meters Biopharma, Inc. (NMTR) Company Bio


9 Meters Biopharma, Inc. operates as a biotechnological company. The Company focuses on development of drugs and treatments for rare disorders and unmet needs. 9 Meters Biopharma serves customers worldwide.


NMTR Latest News Stream


Event/Time News Detail
Loading, please wait...

NMTR Latest Social Stream


Loading social stream, please wait...

View Full NMTR Social Stream

Latest NMTR News From Around the Web

Below are the latest news stories about 9 Meters Biopharma Inc that investors may wish to consider to help them evaluate NMTR as an investment opportunity.

9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference

RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, Inc.

Yahoo | February 9, 2022

Paradigm, Strategies in Wealth Management, LLC Buys iShares iBonds Dec 2023 Term Corporate ETF, ...

Investment company Paradigm, Strategies in Wealth Management, LLC (Current Portfolio) buys iShares iBonds Dec 2023 Term Corporate ETF, iShares iBonds Dec 2023 Term Muni Bond ETF, Costco Wholesale Corp, Prologis Inc, Altria Group Inc, sells iShares iBonds Dec 2021 Term Corporate ETF, iShares iBonds Dec 2021 Term Muni Bond ETF, Wells Fargo, Invesco Preferred ETF, Schwab International Equity ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Paradi

Yahoo | February 8, 2022

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors

RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.

Yahoo | January 24, 2022

Raleigh public company adds former Biogen exec to C-suite

A relatively new biopharmaceutical company in Raleigh has added a new name to its C-suite. 9 Meters Biopharma (Nasdaq: NMTR) has appointed Bethany Sensenig to be chief financial officer. Sensenig is joining the clinical-stage company, which is focused on developing drugs for rare digestive diseases, less than two years after it was formed via a three-way merger that involved a Triangle drugmaker.

Yahoo | January 21, 2022

9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer.

Yahoo | January 18, 2022

Read More 'NMTR' Stories Here

NMTR Price Returns

1-mo -2.30%
3-mo -20.34%
6-mo -56.31%
1-year -64.84%
3-year N/A
5-year N/A
YTD -54.02%
2021 13.93%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.667 seconds.